CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
Abraxanedrug
Likely dose
Abraxane 220 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01730586
NCT01730586Phase 2Completed
CompareCT.gov

Phase II Study of Abraxane in CIMP-High Colorectal Adenocarcinomas and Small Bowel Adenocarcinomas

M.D. Anderson Cancer Center·interventional·Posted Nov 21, 2012·Updated Jan 18, 2020

In Brief

A Phase 2 clinical trial evaluating Abraxane for Colorectal Cancer and Cancer of Gastrointestinal Tract. Completed, enrolled 34 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if abraxane can help to control colorectal and/or small bowel cancer. The safety of this drug will also be studied. Abraxane is designed to block cancer cells from dividing, which may cause them to die.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer, Cancer of Gastrointestinal Tract
CountriesUnited States
CollaboratorsCelgene

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 21, 2012
Enrollment StartNov 1, 2012
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.6 years ago

Interventions

Abraxanedrug

220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.